De Bleecker, Jan L. http://orcid.org/0000-0002-1328-1812
Remiche, Gauthier http://orcid.org/0000-0002-4882-3570
Alonso-Jiménez, Alicia http://orcid.org/0000-0002-2200-9255
Van Parys, Vinciane http://orcid.org/0000-0003-4741-123X
Bissay, Véronique http://orcid.org/0000-0003-3832-8725
Delstanche, Stéphanie http://orcid.org/0000-0003-4481-579X
Claeys, Kristl G. http://orcid.org/0000-0001-9937-443X
Funding for this research was provided by:
Alexion Pharmaceuticals
Argenx
Janssen Pharmaceutica
UCB
Article History
Received: 7 February 2024
Accepted: 31 March 2024
First Online: 22 April 2024
Declarations
:
: JLDB received speaker and/or advisory board honoraria from Alexion, Alnylam, Amicus Therapeutics, argenX, Biogen, CSL Behring, Janssen Pharmaceuticals, Roche, Sanofi-Genzyme, and UCB. GR received speaker and/or advisory board honoraria from Alexion, Alnylam, Amicus Therapeutics, Amlynx, argenX, CSL Behring, Effik, Pfizer, Roche, Sanofi-Genzyme, and UCB. AA received advisory board honoraria from Alexion and UCB. VVP received advisory board honoraria from Alexion, and Alnylam. VB received advisory board honoraria from Alexion and UCB. SD received advisory board honoraria from Alexion, Alnylam, Amicus Therapeutics, Amlynx, argenX, Biogen, CSL Behring, Janssen Pharmaceuticals, and UCB. KGC received speaker and/or advisory board honoraria from Alexion, Alnylam, Amicus Therapeutics, argenX, Biogen, Ipsen, Janssen Pharmaceuticals, Lupin, Pfizer, Roche, Sanofi-Genzyme, and UCB. KGC is Chairholder of the Emil von Behring Chair for Neuromuscular and Neurodegenerative Disorders by CSL Behring.
: This article does not contain any studies with human participates or animals performed by any of the authors.
: For this type of study formal consent is not required.